

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

VOLUNTARY ANNOUNCEMENT

THE RESULTS OF THREE PRECLINICAL STUDIES PRESENTED AT THE AACR 2023

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “**Company**” or “**Jacobio**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the Company presented the results of three preclinical studies of KRAS^{multi} inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 in form of the abstracts during the American Association for Cancer Research (AACR) Annual Meeting 2023 (the “**AACR 2023**”) from April 14, 2023 to April 19, 2023.

Details for the AACR 2023 abstracts are as follows:

Abstract Number:	1660
Title:	Preclinical investigation of orally bioavailable, potent KRAS ^{multi} inhibitor JAB-23425
Session:	Novel Antitumor Agents 4
Time:	April 18, 2023, 9:00 PM – April 18, 2023, 00:30 AM (Beijing time)

KRAS^{multi} inhibitor JAB-23425 targets multiple KRAS mutants in both RAS(ON) and RAS (OFF), with good selectivity over HRAS and NRAS. JAB-23425 has significant inhibitory activity on cancer cells with multiple KRAS mutations (such as G12D, G12V, and G13D) or amplification of wild type KRAS, and has no obvious inhibitory effect on KRAS-independent cells (e.g. cancer cells with BRAF V600E mutation or NRAS mutations, and human normal cells). JAB-23425 shows strong and dose-dependent anti-tumor efficacy on KRAS G12D, G12V and G13D tumor models by oral administration, and animals are well tolerated. Furthermore, JAB-23425 has synergistic effects in combination with cetuximab. JAB-23425 is a leading compound of Jacobio’s KRAS^{multi} inhibitor. Jacobio’s KRAS^{multi} inhibitor is expected to solve the unmet clinical needs of patients with KRAS-mutated tumors.

Abstract Number: 2923
Title: JAB-X1800: a potent immunostimulatory antibody-drug conjugate (iADC) targeting CD73
Session: Therapeutic Antibodies 2
Time: April 18, 2023, 1:30 PM – 5:00 PM (Beijing time)

JAB-X1800 is the world's first iADC by conjugating Jacobio's STING agonist to CD73 antibody, which is expected to turn the tumor from "cold" to "hot". There is significant internalization of JAB-X1800 on CD73-positive cancer cells. JAB-X1800 shows excellent anti-tumor efficacy in CD73-positive xenograft models with well tolerability. A single dose of JAB-X1800 shows sustained anti-tumor activity in hCD73-MC38 syngeneic model and confers immunologic memory when tumor-free mice were re-challenged, and has a synergistic effect with anti-PD-1 mAb.

Abstract Number: 1645
Title: JAB-2485: a potent, highly selective small-molecule Aurora kinase A inhibitor that targets cell division
Session: Novel Antitumor Agents 4
Time: April 17, 2023, 9:00 PM – April 18, 2023, 00:30 AM (Beijing time)

JAB-2485 is one of the top two highly selective Aurora A inhibitors with 1500-fold selectivity over Aurora kinase B and Aurora kinase C, with high activity and low bone marrow toxicity as well as favorable PK properties. JAB-2485 shows strong and dose-dependent anti-tumor efficacy in multiple models as monotherapy. In CDX and PDX models, JAB-2485 shows synergistic anti-tumor activity in combination with chemotherapy drugs.

ABOUT JACOBIO

Jacobio is committed to developing and providing new and innovative products and solutions to improve patients' health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our immunostimulatory antibody-drug conjugate (iADC) Platform.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to obtain further approval for, or ultimately market, KRAS^{multi} inhibitor JAB-23425, CD73-STING iADC JAB-X1800, and Aurora kinase A inhibitor JAB-2485 successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, April 18, 2023

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.